CRMD Quote, Financials, Valuation and Earnings

Axogen has a net margin of -24.24% compared to Cormedix's net margin of -3.82%. Cormedix's return on equity of -72.96% beat Axogen's return on equity of -14.85%.

Cormedix has a consensus price target of --, signalling upside risk potential of 89.62%. On the other hand Axogen has an analysts' consensus of -- which suggests that it could grow by 15.13%. Given that Cormedix has higher upside potential than Axogen, analysts believe Cormedix is more attractive than Axogen.

Cormedix has a beta of 1.543, which suggesting that the stock is 54.28% more volatile than S&P 500. In comparison Axogen has a beta of 1.063, suggesting its more volatile than the S&P 500 by 6.272%.

Cormedix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cormedix pays -- of its earnings as a dividend. Axogen pays out -- of its earnings as a dividend.

Cormedix quarterly revenues are $11.5M, which are smaller than Axogen quarterly revenues of $48.6M. Cormedix's net income of -$2.8M is lower than Axogen's net income of -$1.9M. Notably, Cormedix's price-to-earnings ratio is -- while Axogen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cormedix is -- versus 3.76x for Axogen. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -24.24% compared to Cormedix's net margin of -49.65%. Cormedix's return on equity of -72.96% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Cormedix has a consensus price target of --, signalling upside risk potential of 89.62%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 602.96%. Given that NovaBay Pharmaceuticals has higher upside potential than Cormedix, analysts believe NovaBay Pharmaceuticals is more attractive than Cormedix.

Cormedix has a beta of 1.543, which suggesting that the stock is 54.28% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Cormedix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cormedix pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Cormedix quarterly revenues are $11.5M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Cormedix's net income of -$2.8M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Cormedix's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cormedix is -- versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -24.24% compared to Cormedix's net margin of -2357.27%. Cormedix's return on equity of -72.96% beat Palatin Technologies's return on equity of --.

Cormedix has a consensus price target of --, signalling upside risk potential of 89.62%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1656.38%. Given that Palatin Technologies has higher upside potential than Cormedix, analysts believe Palatin Technologies is more attractive than Cormedix.

Cormedix has a beta of 1.543, which suggesting that the stock is 54.28% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

Cormedix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cormedix pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Cormedix quarterly revenues are $11.5M, which are larger than Palatin Technologies quarterly revenues of $350K. Cormedix's net income of -$2.8M is higher than Palatin Technologies's net income of -$7.8M. Notably, Cormedix's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cormedix is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Rockwell Medical has a net margin of -24.24% compared to Cormedix's net margin of 5.88%. Cormedix's return on equity of -72.96% beat Rockwell Medical's return on equity of -5.32%.

Cormedix has a consensus price target of --, signalling upside risk potential of 89.62%. On the other hand Rockwell Medical has an analysts' consensus of -- which suggests that it could grow by 212.5%. Given that Rockwell Medical has higher upside potential than Cormedix, analysts believe Rockwell Medical is more attractive than Cormedix.

Cormedix has a beta of 1.543, which suggesting that the stock is 54.28% more volatile than S&P 500. In comparison Rockwell Medical has a beta of 1.379, suggesting its more volatile than the S&P 500 by 37.916%.

Cormedix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rockwell Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cormedix pays -- of its earnings as a dividend. Rockwell Medical pays out -- of its earnings as a dividend.

Cormedix quarterly revenues are $11.5M, which are smaller than Rockwell Medical quarterly revenues of $28.3M. Cormedix's net income of -$2.8M is lower than Rockwell Medical's net income of $1.7M. Notably, Cormedix's price-to-earnings ratio is -- while Rockwell Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cormedix is -- versus 0.64x for Rockwell Medical. Usually stocks with elevated PS ratios are considered overvalued.